Business & Industry
- Pfizer files lawsuit against Metsera and its directors and Novo Nordisk for breach of merger agreement
- Pfizer receives early clearance from U.S. Federal Trade Commission for Metsera acquisition
- Pfizer addresses proposal for Metsera
- Bayer's Lynkuet™ (elinzanetant) approved in the U.S. for treatment of moderate to severe vasomotor symptoms due to menopause
- Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
Research & Development
- How the cheese-noodle principle could help counter Alzheimer's
- New 'sensor' lets researchers watch DNA repair in real time
- The immune system creates its own targets within viruses
- Targeted drug could benefit young patients with invasive sarcoma
- Next-generation microbiome medicine may revolutionize the treatment of Parkinson's and similar disorders
- A cellular protein, FGD3, boosts breast cancer chemotherapy, immunotherapy
- Common gout drug may reduce risk of heart attack and stroke
Conferences & Events
- Cohort data from Denmark show real-world evidence of stable protection against HPV-related cervical cancer
- New insights into T and B cells offer hope for autoimmune disease sufferers
- SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
- SAE Media Group's 6th annual 3D Cell Culture Conference
- CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
- 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
- CPHI Excellence in Pharma Award Winners 2022
Regulatory Affairs
- FDA approves first gene therapy for treatment of aromatic L-amino acid decarboxylase deficiency
- FDA approves new treatment for hemophilia A or B
- FDA approves nasal spray influenza vaccine for self- or caregiver-administration
- FDA approves first nasal spray for treatment of anaphylaxis
- FDA approves nonsteroidal treatment for Duchenne muscular dystrophy